-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSWhite Paper
National Ownership of Antibiotic Access and Use: Driving Policy Decision-Making Based on Population Needs
Sep 25, 2024
This paper discusses the development of national antibiotic assessment reports (NAARs) as foundations for the design of national antibiotic policies. It proposes that more robust national data on antibiotic use that integrates population health factors can support equitable access to these medicines and inform global targets. Overall, a better and more accurate understanding of antibiotic use can increase national ownership and curb the impact of antimicrobial resistance (AMR).
Antimicrobial resistance (AMR) is one of the most pressing global public health threats today. As microorganisms evolve and no longer respond to available treatments, the options for managing and preventing severe infections become limited. This not only increases the risk of complications, hospital admissions, and death but also threatens advances in medical care. Recent outbreaks and pandemics have further underscored the far-reaching consequences of infectious diseases without effective treatment, raising critical questions about preparedness and global coordinated action.
To address these challenges, the World Health Organization (WHO) has systematically provided guidance and tools to support countries in combating AMR. Such efforts include global targets, stewardship protocols, and parameters for national action plans (NAPs). However, current trends in antibiotic use and the rising deaths attributed to bacterial resistance, estimated at 4.95 million in 2019, suggest the need for different approaches.
This white paper discusses the development of national antibiotic assessment reports (NAARs) as foundations for designing national antibiotic policies. By using a single standard method to combine multiple antibiotic use datasets within these reports, information can be made comparable within and across countries. Therefore, creating a more comprehensive assessment of antibiotic use, factoring in population health factors, could increase national ownership and improve the AMR response.
The paper is divided into three parts:
- Understanding antibiotic use in humans: This section discusses global trends in antibiotic use over the last decade, reflects on current efforts and challenges to develop new anti-infectives, and highlights the barriers to collecting and processing the right data on AMR. An analysis of IQVIA data covering pharmacy sales in 87 countries from 2013 to 2023 shows an increase in antibiotic use worldwide, with noticeable variations across regions. The antibiotics selected for review are representative of the Access, Watch, and Reserve (AWaRe) groups, a WHO classification set in 2017 to support surveillance and ensure appropriate use and long-term stewardship.
- The need for standardized NAARs: This section delves into the need for detailed antibiotic use assessments, including metrics to better inform national antibiotic policies and monitor progress. It presents an analysis of gaps in current NAPs and emphasizes the importance of comprehensive data collection and responsible antibiotic use. The paper proposes that more robust global and national data on antibiotic use can streamline procurement and financial decisions and, in turn, support equitable access to these medicines.
- Partnership frameworks as catalysts for NAARs and national antibiotic policies: The final section elaborates on the partnership frameworks required to formulate NAARs and national antibiotic policies. It discusses the potential integration of multi-disciplinary technical capabilities across key stakeholders to better monitor antibiotic use and the trajectory of AMR.
By providing a comprehensive assessment of antibiotic use and proposing robust data collection methods, this paper ultimately aims to support the development of effective national antibiotic policies and optimize the global response to AMR.